Amicus Therapeutics Appoints Simon Harford as CFO; Daphne Quimi to Retire by Year End

AMICUS THERAPEUTICS, INC.

Simon Harford appointed CFO effective August 21, 2023; replaces Daphne Quimi who will retire at year end.
Harford receives base salary $500,000, bonus target 45% of salary, and initial equity award valued at $2.7M.
Company reiterates expectation to achieve profitability in second half of 2023.
Harford previously served as CFO of Albireo Pharma and Parexel; 30+ years healthcare finance experience.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Simon Harford

Chief Financial Officer

AMICUS THERAPEUTICS, INC.

Effective: 2023-08-21
Filed: August 21, 2023, 7:59 PM ET

appointed Simon Harford as the Chief Financial Officer (principal financial officer) of the Company, effective as of August 21, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Simon Harford was appointed as Chief Financial Officer at AMICUS THERAPEUTICS, INC..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

appointed Simon Harford as the Chief Financial Officer (principal financial officer) of the Company, effective as of August 21, 2023.

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-23-093669

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.